Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatmentOptional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a